Sofinnova Partners Congratulates Portfolio Company DNA Script for the Success of Its €142M ($165M) Oversubscribed Series C Fundraise
26.10.2021 16:00:00 EEST | Business Wire | Press release
Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today that its portfolio company DNA Script has raised €142 million ($165 million) in a Series C financing led by top global investors, bringing the total amount raised to date by the company to €236 million ($280 million). DNA Script is a pioneer in Enzymatic DNA Synthesis (EDS) and DNA printing on demand. The new funds will be used to accelerate expansion and commercialization of the company’s revolutionary SYNTAX Platform and broaden the portfolio of products powered by EDS.
DNA Script is a leader in enzymatic DNA synthesis and has developed a revolutionary platform that provides in-house DNA printing using a sustainable process that eliminates the use of toxic organic chemicals. The company’s ground-breaking approach to DNA printing significantly shortens wait times by enabling labs of all sizes to take full control of their DNA printing needs from the comfort of their own facilities – like having a home printer. No longer having to rely on third-party providers, researchers gain unprecedented control and autonomy, ultimately helping to accelerate innovation.
Joško Bobanović, Partner at Sofinnova Partners, said: “As the first institutional investor in DNA Script, it is incredibly gratifying to have been part of the growth and evolution of the company from the start. This milestone confirms our early conviction in the strength of the team and the magnitude of their vision to revolutionize a well-established chemical technology by applying biotechnology. The overwhelming interest from the global community further affirms our long-standing belief in the uniqueness and potential of the company’s technology to fundamentally change how DNA is synthesized by mimicking nature, while remaining entirely sustainable.”
Thomas Ybert, co-founder and CEO of DNA Script, said: “Sofinnova Partners was our first institutional investor and a strong believer in our vision from the beginning. Their hands-on role throughout critical early-stage financing rounds, and as an active member of our Board of Directors, has been instrumental in enabling us to rapidly scale to become a global operation and attract top notch investors from all over the world.”
The Sofinnova Industrial Biotech strategy is part of Sofinnova’s multi-fund investment platform that covers the entire life sciences value chain. It is a highly-targeted strategy that seeks to invest in start-ups that are addressing global sustainability issues in food, agricultural, chemicals and materials markets.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: www.sofinnovapartners.com
About DNA Script
Founded in 2014, DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, allowing this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System. By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy. www.dnascript.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005360/en/
Contact information
Bommy Lee
Head of Communications, Sofinnova Partners
blee@sofinnovapartners.com
+33 (0) 6 47 71 38 11
North America
RooneyPartners LLC
Kate Barrette
kbarrette@rooneypartners.com
+1 212 223 0561
France
StrategiesImage
Anne Rein
anne.rein@strategiesimage.com
+33 (0) 6 03 35 92 05
Italy
Havas PR Milan
Rafaella Casula
rafaella.casula@havaspr.com
+39 (0) 345 3780834
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 14:00:00 EET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 13:00:00 EET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP) Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 Constraints Not Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. C
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 10:15:00 EET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 09:18:00 EET | Press release
Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers compared to currently available technologies. This in turn is boosting expectations
EdgeConneX Looks to Enter Swedish Market as Part of European Data Center Expansion Strategy27.2.2026 09:05:00 EET | Press release
EdgeConneX®, an EQT portfolio company with an extensive Pan-European data center footprint, looks to expand its presence with a new site located in Skellefteå, Sweden. The data center site will be acquired from Lyten, a global company that specializes in lithium-sulfur batteries and energy storage. The site would support EdgeConneX broader strategy to expand digital infrastructure capacity across the Nordics. Subject to the completion of applicable administrative and regulatory processes, EdgeConneX will look to develop a data center campus with potential capacity of up to one gigawatt in support of future AI and cloud computing workloads. Upon completion, the data center campus would be one of the largest facilities in Europe that would be primarily powered by renewable energy. “Sweden represents an attractive long‑term market for digital infrastructure investment. The country’s access to renewable energy, stable power grid, technical workforce and strong sustainability framework alig
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom